HeartSciences touts MyoVista LVDD study
HeartSciences today released results from a clinical study of its MyoVista electrocardiogram system, touting its ability to detect myocardial relaxation abnormalities associated with left ventricular diastolic dysfunction.
Results from the trial were published in the Journal of the American College of Cardiology, the Southlake, Texas-based company said.
“This study of MyoVista wavelet ECG technology is a significant step towards enhancing the most commonly used low-cost, front-line tool, the 12-lead resting ECG, with new capabilities that can provide more effective risk stratification related to the early detection of heart disease,” board chair Andrew Simpson said in a prepared release.
Data from the 188-patient study indicated an 80% sensitivity and 84% specificity with an area under the curve of 91% for predicting low (e’), which is used to determine LVDD. Prediction of low (e’) was identified in 82% of subjects with significant underlying coronary artery disease.
HeartSciences said that the MyoVista wavECG prediction of relaxation abnormalities also allowed the recognition of subjects with more advanced stages of DD and concurrent CAD compared to conventional ECG info.
“These data are extremely encouraging as they suggest a potential role of signal processed ECG in early cardiac disease detection. It is quite remarkable that MyoVista demonstrated a high diagnostic precision in detecting a state of cardiac muscle dysfunction only previously detectable using cardiac ultrasound techniques. This can eventually help in appropriate cardiac testing and reduce overall healthcare costs,” principal investigator Dr. Partho Sengupta of the WVU Heart & Vascular Institute said in a press release.
The company said that results indicated a possible role for the MyoVista wavECG device as a screening tool for patients at risk of LVDD.
“These positive results demonstrate that MyoVista wavECG Technology, which includes our patented signal processing methods combined with artificial intelligence, can lead to enhanced capabilities and completely new uses for electrocardiography-based (ECG) devices,” prez & CEO Mark Hilz said in prepared remarks.